American Resources Corporation (NASDAQ:AREC), a next generation and socially responsible supplier of rare earth and critical elements, carbon and advanced carbon materials to the new infrastructure and electrification marketplace, announced that it has commenced initial production at its greenfield Carnegie 2 metallurgical carbon operation ahead of schedule. Following the mine's initial development production, the Company will increase the output of its Carnegie 2 mine over the next several months to fully expand and maximize production, revenues and cash flow.

EV Technology Group Ltd. (NEO: EVTG) (OTCQB: EVTGF) (DE: B96A) announced that it has entered into a definitive agreement with the shareholders of MOKE International to acquire up to 100% of MOKE International Limited, its first purchase of a major iconic brand. This strategically crucial acquisition adds to EV Technology Group’s house of iconic brands, and it will continue to grow the UK-based company MOKE International, which is now introducing the Electric MOKE to the global market. The Acquisition is expected to close later in the year.

Medigus Ltd. (NASDAQ: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced that Polyrizon Ltd., an Israeli biotech company that specializes in innovative intranasal products in which Medigus owns 37.03%, signed a binding Collaboration Agreement with NurExone Biologic Inc. (TSXV: NRX), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries. Under the Collaboration Agreement, NurExone will cover the costs of the formulation development in an estimated amount of USD 220,000 in 3 installments upon development success and expects to be able to perform a biological efficacy study of the intranasal system within 3 quarters.

Second Sight Medical Products, Inc. (NASDAQ: EYES), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, announced that the Company received notice from the National Institutes of Health (NIH) of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, known as the “Orion Trial”, grant 5UH3NS103442. The NIH released $1.1 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial. The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.